Moreira T, Mangani D, Cox L, Leibowitz J, Lobo E, Oliveira M, et al. PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nat Commun. 2021;12:4907 pubmed publisher

Pan Y, Shu G, Fu L, Huang K, Zhou X, Gui C, et al. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. Adv Sci (Weinh). 2023;10:e2206792 pubmed publisher

Tunal x131 G, R xfa bies Bed xf3 s M, Nagarajan D, Fridh P, Papakyriacou I, Mao Y. IL-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy. J Clin Invest. 2023;133: pubmed publisher

Hu K, Wu W, Xie L, Geng H, Zhang Y, Hanyu M, et al. Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors. Acta Pharm Sin B. 2022;12:1363-1376 pubmed publisher

Sawasdee N, Wattanapanitch M, Thongsin N, Phanthaphol N, Chiawpanit C, Thuwajit C, et al. Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors. Int J Mol Med. 2022;49: pubmed publisher

Wen M, Cao Y, Wu B, Xiao T, Cao R, Wang Q, et al. PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain. Nat Commun. 2021;12:5106 pubmed publisher

Petersen S, Kua L, Nakajima S, Yong W, Kono K. Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer. Sci Rep. 2021;11:12264 pubmed publisher

Li H, Liu Y, Chen L, Zhou J, Chen D, Li S, et al. CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma. Mol Carcinog. 2021;60:556-566 pubmed publisher

Ghosh S, Nataraj N, Noronha A, Patkar S, Sekar A, Mukherjee S, et al. PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Cell Rep. 2021;35:109181 pubmed publisher

Chen L, Yang Q, Li Y, Yang L, Liu J, Li H, et al. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Cancer Immunol Res. 2020;8:179-191 pubmed publisher

Abd Hamid M, Colin York H, Khalid Alham N, Browne M, Cerundolo L, Chen J, et al. Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses. Cancer Immunol Res. 2020;8:203-216 pubmed publisher